Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • ErbB Receptors
  • Neoplasms
  • Organic Chemicals

abstract

  • The MTD of once-daily oral EKB-569 is 75 mg. The tolerable toxicity profile and long half-life of this irreversible EGFR inhibitor warrant its further evaluation as a single agent and in combination with other drugs.

publication date

  • May 20, 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.01.8960

PubMed ID

  • 16710023

Additional Document Info

start page

  • 2252

end page

  • 60

volume

  • 24

number

  • 15